سعر اوسوفورتين 1.25 مجم 50.000 وحدة دولية 30 قرص 2024

Ossofortin ergocalciferol (vitamin D2) 1.25 mg (50,000 IU) tablets, 30 per pack, by Eva Pharma.

• Hypoparathyroidism, refractory (vitamin D-resistant) rickets and familial hypophosphataemiaDailyMed (U.S. National Library of Medicine)

• Adverse effects reflect hypervitaminosis D: hypercalcaemia with anorexia, nausea, weakness and constipation; renal impairment (polyuria, polydipsia, nephrocalcinosis); soft-tissue calcification; bone demineralisation.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Hypercalcaemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• The range between therapeutic and toxic doses is narrow; dosing must be individualised under close medical supervision, with serum calcium and phosphorus checked every 2 weeks or more often.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Mineral oilMineral oil interferes with the absorption of vitamin D.DailyMed (U.S. National Library of Medicine)
• Thiazide diureticsThiazides given to hypoparathyroid patients on ergocalciferol may cause hypercalcaemia.DailyMed (U.S. National Library of Medicine)

• Hypervitaminosis D caused fetal abnormalities in animals; vitamin D in excess of the recommended dietary allowance should be avoided in normal pregnancy unless benefits outweigh risks.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Use with caution in nursing women; large maternal doses have caused hypercalcaemia in a breastfed infant, so infant serum calcium should be monitored.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

English text not available for this section.